Printer Friendly

BAXTER INTERNATIONAL/APPLIED IMMUNE SCIENCES SIGN LICENSE FOR STEM CELL PATENTS

 DEERFIELD, Ill., and SANTA CLARA, Calif., Jan. 18 /PRNewswire/ -- Baxter International's Biotech Group (NYSE: BAX) and Applied Immune Sciences (AIS) (NASDAQ-NMS: AISX) announced today that they have finalized an agreement granting AIS a non-exclusive license covering certain patents for anti-CD34 antibodies and stem cell populations. The antibodies will be used in conjunction with AIS' proprietary stem cell separation device, the AIS CELLector(TM). This license is the first issued by Baxter for its stem cell patents.
 "Baxter's Biotech Group is pleased to have reached an agreement with AIS for these important patents," said John Osth, president, Baxter Biotech, Immunotherapy Division. "We believe this technology will contribute to the therapy of patients with serious diseases that attack the immune system."
 James Smith, AIS' senior vice president and chief operating officer, said, "AIS regards the patents as offering great value to our continued development of proprietary products and services."
 Stem cells are the cells in the blood and bone marrow from which all blood cells, including those of the immune system are derived. The goal of stem cell therapy is to separate the stem cells from the blood or bone marrow and process them to enhance their immune capabilities, after which they are re-infused into the patient.
 "The CD34 antibodies are used to identify the stem cells, but in order for stem cell therapy to be successful, the cells must be collected and processed in a device such as AIS' CELLector(TM)," said Smith.
 The non-exclusive license granted to AIS is based on patents held by Curt Civin, M.D., associate professor of pediatrics and oncology at Johns Hopkins Medical Center. These patents that cover anti-CD34 antibodies, populations of cells that express the CD34 antigen, and processes by which these cells are extracted from human bone marrow and blood. Johns Hopkins and its research partner, Becton Dickinson and Company, exclusively licensed this technology to Baxter in 1990 for therapeutic uses. The technology involved is the basis for future research in human gene therapy.
 Bone marrow transplantion is a growing area of cancer treatment. More than 11,000 bone marrow transplants are performed worldwide each year. Recent U.S. Food and Drug Administration approvals of factors that stimulate the growth of selected cells may increase the use of bone marrow transplant therapy in the treatment of cancer and other diseases.
 AIS, a pioneering company in cell therapy, focuses on the development and manufacture of products that manipulate the immune system outside the body, restoring and enhancing the ability of patients with serious diseases to respond to treatment. AIS' proprietary technology is teamed with the capability of delivering these therapies in the hospital, in the clinic, and in the home, through a growing worldwide network of Cell Therapy centers.
 Baxter Biotech's Immunotherapy Division, based in Santa Ana, Calif., is a leading supplier of cell separation and stem cell technologies to the transfusion medicine community. The division's aggressive research and development program concentrates on the use of monoclonal antibodies and other innovative technologies to enhance the human immune system to fight and cure disease. Baxter Biotech is working collaboratively with strategic partners to develop curative therapies in the areas of cancer, blood therapy and genetic disorders. Products developed by Baxter Biotech are distributed to health-care settings in more than 100 countries around the world.
 Baxter International, headquartered in Deerfield, is the leading manufacturer and marketer of health-care products, systems and services worldwide. The company offers more than 120,000 products to health-care providers around the world and has research and development programs in biotechnology, diagnostics, cardiovascular medicine, renal therapy and other medical fields.
 -0- 1/18/93
 /CONTACT: Robert Goodenow, Ph.D. of Baxter Biotech, 714-553-0330; or Mary Curtin for Baxter Biotech, 212-685-1900; or Susan Meister, 714-721-8081, or Jerry Ford, 408-980-5829, both for Applied Immune Sciences/
 (BAX)


CO: Baxter International; Applied Immune Sciences ST: Illinois, California IN: MTC SU: LIC

TS -- NY019 -- 5805 01/18/93 10:06 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 18, 1993
Words:654
Previous Article:GLAXO DOUBLES IT'S PARTICIPATION IN BIOCHEM PHARMA INC.
Next Article:FAST-GROWTH COMPANIES ANTICIPATE NEW ADMINISTRATION WILL BE SUCCESSFUL IN IMPLEMENTING INCENTIVES TO STIMULATE GROWTH: COOPERS & LYBRAND SURVEY
Topics:


Related Articles
BAXTER, CANTAB EXPAND COLLABORATION ON ANTI-CD45 ANTIBODY TO PREVENT ORGAN-TRANSPLANT REJECTION
AASTROM BIOSCIENCES AND RHONE-POULENC RORER ENTER $25 MILLION COLLABORATION IN LYMPHOID CELL AND GENE THERAPIES
Baxter: Federal Jury Awards $2.3 Million to Johns Hopkins, Baxter and Becton Dickinson in Patent Infringement Case
Federal Appeals Court Upholds Judgment in Patent Dispute Over Stem Cell Selection Technology
Immunex Awarded Method of Use Patent on Mobist(TM).
Baxter Prevails in Sevoflurane Patent Dispute.
Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods.
Stem Cell Sciences Signs Service Agreement With Pfizer to Provide Access to Proprietary Technologies and Methods.
Stem Cell Sciences Signs Agreement With Pfizer.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters